Table 3.
Subgroup analysis of treatment with interleukin inhibitors in patients diagnosed with COVID-19, respiratory failure, and hyperinflammation
|
Mortality (Cox regression analysis*) |
Adverse clinical outcome (Cox regression analysis*) |
|||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Treatment and C-reactive protein | ||||
| No interleukin inhibitors | 1 (ref) | .. | 1 (ref) | .. |
| IL-1 inhibitor by C-reactive protein | 0·994 (0·985–1·004) | 0·23 | 0·997 (0·991–1·003) | 0·31 |
| IL-6 inhibitor by C-reactive protein | 0·990 (0·981–0·999) | 0·031 | 0·987 (0·979–0·995) | 0·0021 |
| Treatment and lactate dehydrogenase | ||||
| No interleukin inhibitors | 1 (ref) | .. | 1 (ref) | .. |
| IL-1 inhibitor by lactate dehydrogenase | 1·009 (1·003–1·014) | 0·0011 | 1·006 (1·002–1·010) | 0·0031 |
| IL-6 inhibitor by lactate dehydrogenase | 1·006 (1·001–1·011) | 0·028 | 1·005 (1·001–1·010) | 0·016 |
HR=hazard ratio. IL=interleukin.
*
Model adjusted for age, C-reactive protein, and lactate dehydrogenase.